BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 5, 2026
Home » Monthly Med-tech Deals Analysis

Articles Tagged with ''Monthly Med-tech Deals Analysis''

Med-tech deals September 2023

Despite September slowdown, med-tech deal value hits $9.83B through Q3

Oct. 16, 2023
By Amanda Lanier
Med-tech deals are up 49.01% year over year, with the industry raising $9.83 billion through September in 2023, up from $6.59 billion in the same time frame last year. The number of deals, meanwhile, has decreased from 1,510 through Q3 2022 to 1,278 this year.
Read More

Exor-Philips deal tops charts as industry’s largest; overall med-tech deals up 90% YOY

Sep. 15, 2023
By Amanda Lanier

Med-tech deal values continued their upward swing, increasing nearly 90% from last year. Med-tech M&A volume and value remained in a slump compared to the previous two years, though values are higher than 2020.


Read More
Green arrow up red arrow down

Med-tech deals reach $8.63B and M&As total $37.33B in first 7 months of 2023

Aug. 14, 2023
By Amanda Lanier
Med-tech deal values the first seven months of the year are up more than 50% from last year. Meanwhile, M&As decreased almost 70% from the same time period in 2022.
Read More
Handshake with dollar sign and checkmark
Med-tech deals June 2023

Med-tech deal value up more than 100% YOY, monthly M&As at 2-year low

July 14, 2023
By Amanda Lanier
Year over year, med-tech deal values were up more than 100% in June, while the value of mergers and acquisitions decreased by nearly 100%.
Read More
Med-tech deals May 2023

Med-tech deal value doubles from same time period last year

June 13, 2023
By Amanda Lanier
In the first five months of 2023, med-tech deal value is at the highest amount in recent years – up 128.219% from last year – while deal volume has decreased by 12.29%. Through May this year, 742 med-tech deals have raised a potential $5.38 billion, compared to 846 deals totalling $2.36 billion last year. The two recent years are vastly more than 2021, when through May there were 661 deals raising $386.69 million.
Read More
Med-tech deals April 2023

Med-tech deals surge to highest value in years as M&As slow down

May 19, 2023
By Amanda Lanier
Med-tech has seen significant deal value growth during the first four months of 2023, despite a decline in the number of deals. In contrast, the value of mergers and acquisitions has experienced a notable downturn.
Read More
Previous 1 2 3 4 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 2, 2026.
  • Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

    Small-molecule TREM2 agonist advances to treat Alzheimer’s

    BioWorld Science
    Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
  • Amyloid beta peptides on neurons

    Amlogenyx’s AM-805 reduces amyloid plaques in AD

    BioWorld Science
    The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 31, 2026
  • Atai Therapeutics patents new 5-HT2 receptor agonists

    BioWorld Science
    Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing